Nektar Therapeutics (NKTR) Receivables (2010 - 2025)
Nektar Therapeutics (NKTR) posted quarterly Receivables of $1.0 million for Q4 2025, down 9.09% year-over-year from $1.1 million in Q4 2024, and up 400.0% quarter-over-quarter from $200000.0 in Q3 2025.
Nektar Therapeutics (NKTR) Receivables (2010 - 2025) Analysis & Trends
Nektar Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $1.0 million for Q4 2025.
- In Q4 2025, Receivables fell 9.09% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 9.09% YoY), while the FY2025 annual figure was $1.0 million, down 9.09% from the prior year.
- Receivables for Q4 2025 stood at $1.0 million, up from $200000.0 in the prior quarter.
- The five-year high for Receivables was $30.2 million in Q1 2022, with the low at $200000.0 in Q3 2025.
- The 5-year median for Receivables is $3.6 million (2024), against an average of $10.9 million.
- The sharpest annual moves came in 2023 and 2024: Receivables slumped 90.09% in 2023, then advanced 20.77% in 2024.
- Nektar Therapeutics' Receivables stood at $23.9 million in 2021, then sank by 72.04% to $6.7 million in 2022, then slumped by 74.48% to $1.7 million in 2023, then slumped by 35.48% to $1.1 million in 2024, then dropped by 9.09% to $1.0 million in 2025.
- Business Quant data shows NKTR's Receivables at $1.0 million in Q4 2025, $200000.0 in Q3 2025, and $1.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 200,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 3.62 Mn |
| Dec 31, 2023 | 1.71 Mn |
| Sep 30, 2023 | 2.20 Mn |
| Jun 30, 2023 | 1.34 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | 6.68 Mn |
| Sep 30, 2022 | 11.53 Mn |
| Jun 30, 2022 | 10.01 Mn |
| Mar 31, 2022 | 30.22 Mn |
| Dec 31, 2021 | 23.89 Mn |
| Sep 30, 2021 | 28.99 Mn |
| Jun 30, 2021 | 28.87 Mn |
| Mar 31, 2021 | 29.16 Mn |
| Dec 31, 2020 | 43.99 Mn |
| Sep 30, 2020 | 48.33 Mn |
| Jun 30, 2020 | 53.35 Mn |